Homechevron_rightAll Peptideschevron_rightRetatrutide

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-15mg

Official Product Data Sheet

Retatrutide (15mg)

Ultra High >99.5% Purity

Vial Contents

15 mg Retatrutide (lyophilized powder)

Includes

3 ml bacteriostatic water for reconstitution

Form

Lyophilized white powder for optimal stability

Purity

≥98%, third-party tested (COA available)

Sequence

Long-acting triple agonist (proprietary structure)

Molecular Formula

C₂₂₃H₃₄₃N₅₃O₇₀S₂

Molecular Mass

~4731 g/mol

CAS No.

2381089-83-2

Solubility

Reconstitute with sterile/bacteriostatic water (3 ml for ~5 mg/mL)

Storage

Lyophilized frozen; reconstituted refrigerated at 2–8°C for up to 28 days

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

swipe_rightSwipe to see all tabs

Scientific Background

Ready for serious fat loss? This higher-dose triple agonist crushes cravings, torches fat, and delivers up to 24% weight reduction—proven in trials.

If 10mg got you started, 15mg accelerates everything. Watch stubborn pounds vanish faster while energy soars. The triple action suppresses hunger, boosts fat burn, and ramps energy use—leading to dramatic, sustained loss.

Trials prove it: 15mg weekly led to 22-24% loss over 48 weeks, with huge drops in liver fat (82%) and HbA1c (~2%). The glucagon boost burns calories like exercise—perfect for stubborn fat that won't budge.

Intended Research Use

Achieves massive weight loss (up to 24%)
Targets visceral fat and reverses liver issues
Improves insulin sensitivity, lipids, and overall metabolic health
Drops HbA1c by ~2% in diabetes patients

menu_bookScientific Publications

article

N Engl J Med (2023)

Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/

article

Lancet (2023)

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364343/

article

Nat Med (2024)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/38877164/

Clinical Evidence: Trials prove it: 15mg weekly led to 22-24% loss over 48 weeks, with huge drops in liver fat (82%) and HbA1c (~2%). The glucagon boost burns calories like exercise—perfect for stubborn fat that won't budge.

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Clinical research suggests combining Retatrutide with complementary peptides can enhance weight management outcomes.

Cagrilintide (5mg vial)

arrow_forward

myo-cagrilintide-5mg

Maxes satiety for even faster weight loss.

AOD-9604 (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Hits fat pockets hard while Retatrutide handles metabolism.

Semaglutide (5mg vial)

arrow_forward

myo-semaglutide-5mg

Amplifies GLP-1 for unbeatable hunger control.

Mazdutide 5mg (5mg vial)

arrow_forward

myo-mazdutide-5mg

Dual GLP-1/glucagon agonist with similar 20–24% weight loss outcomes — compared with Retatrutide in trials exploring dual vs. triple receptor activation.

Survodutide 10mg (10mg vial)

arrow_forward

myo-survodutide-10mg

GLP-1/glucagon dual agonist with particular hepatic fat reduction benefits — studied alongside Retatrutide for overlapping appetite regulation mechanisms.

schedule

Cycling Note: Once-weekly for 12+ weeks (trials to 48 weeks).